{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:44:23Z","timestamp":1792673063419,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019349","name":"Nanjing Medical Science and Technique Development Foundation","doi-asserted-by":"publisher","award":["YKK22223"],"award-info":[{"award-number":["YKK22223"]}],"id":[{"id":"10.13039\/501100019349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304467"],"award-info":[{"award-number":["82304467"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703342"],"award-info":[{"award-number":["81703342"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["SJCX22_0789"],"award-info":[{"award-number":["SJCX22_0789"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308200"],"award-info":[{"award-number":["2023YFC2308200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007956","name":"Nanjing University of Chinese Medicine","doi-asserted-by":"publisher","award":["ZYXJC2024-007"],"award-info":[{"award-number":["ZYXJC2024-007"]}],"id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211301"],"award-info":[{"award-number":["BK20211301"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118199","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:28:35Z","timestamp":1759012115000},"page":"118199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Highly potent and selective degrader targeting ER\u03b1 to improve the treatment outcomes of breast cancer"],"prefix":"10.1016","volume":"301","author":[{"given":"Xueting","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunkai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhenZhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118199_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118199_bib2","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118199_bib3","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","article-title":"Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer","volume":"12","author":"Prat","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118199_bib4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118199_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118199_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118199_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118199_bib8","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/1097-0142(197307)32:1<31::AID-CNCR2820320104>3.0.CO;2-5","article-title":"Preliminary trial of aminoglutethimide in breast cancer","volume":"32","author":"Griffiths","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.118199_bib10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.2001.19.3.881","article-title":"Aromatase inhibitors in the treatment and prevention of breast cancer","volume":"19","author":"Goss","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118199_bib11","article-title":"Aromatase inhibitors: role in postmenopausal breast cancer","volume":"353","author":"Kharb","year":"2020","journal-title":"Arch. Pharm. (Weinh.)"},{"key":"10.1016\/j.ejmech.2025.118199_bib12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118199_bib13","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.ejmech.2025.118199_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118199_bib15","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1158\/1078-0432.CCR-18-1569","article-title":"Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial","volume":"24","author":"Paoletti","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118199_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/tpj.2014.34","article-title":"Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer","volume":"15","author":"Saladores","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.ejmech.2025.118199_bib17","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.1039\/D2CS00117A","article-title":"SERDs: a case study in targeted protein degradation","volume":"51","author":"Wang","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.118199_bib18","doi-asserted-by":"crossref","first-page":"15094","DOI":"10.1021\/acs.jmedchem.0c00913","article-title":"Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive endocrine-resistant breast cancer","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/00003495-200161060-00013","article-title":"Fulvestrant","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118199_bib20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clbc.2011.02.002","article-title":"Fulvestrant revisited: efficacy and safety of the 500-mg dose","volume":"11","author":"Howell","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ejmech.2025.118199_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.7-6-477","article-title":"FDA drug approval summaries: fulvestrant","volume":"7","author":"Bross","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.118199_bib22","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-16-2561","article-title":"Elacestrant (RAD1901), a Selective Estrogen receptor degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models","volume":"23","author":"Bihani","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118199_bib23","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.5b00054","article-title":"Identification of GDC-0810 (ARN-810), an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts","volume":"58","author":"Lai","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib24","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/0008-5472.CAN-15-2357","article-title":"AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-Positive and ESR1-Mutant breast tumors in preclinical models","volume":"76","author":"Weir","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118199_bib25","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (Giredestrant): a potent and orally bioavailable selective Estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor \u03b1 for degradation with PROTACs: a promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00018-019-03281-4","article-title":"Mechanisms of resistance to estrogen receptor modulators in ER+\/HER2- advanced breast cancer","volume":"77","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.118199_bib28","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118199_bib29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-Induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118199_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118199_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118199_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118199_bib34","article-title":"Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","author":"Snyder","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118199_bib35","article-title":"Abstract 44: the discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118199_bib36","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118199_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118199_bib38","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1021\/acs.jcim.3c01503","article-title":"Hot-spot residue-based virtual screening of novel selective estrogen-receptor degraders for breast cancer treatment","volume":"63","author":"Dai","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118199_bib39","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib40","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1021\/acs.jmedchem.3c01789","article-title":"Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP\/p300 PROTAC degrader for the treatment of advanced prostate cancer","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib41","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1021\/acs.jmedchem.3c00405","article-title":"Discovery of ARD-2051 as a potent and orally efficacious proteolysis targeting chimera (PROTAC) degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"66","author":"Han","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib42","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1021\/acs.jmedchem.4c01009","article-title":"Discovery of AK-1690: a potent and highly selective STAT6 PROTAC degrader","volume":"68","author":"Kaneshige","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib43","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1021\/acs.jmedchem.2c02032","article-title":"Discovery of a novel class of PROTACs as potent and selective Estrogen receptor \u03b1 degraders to overcome endocrine-resistant breast cancer in vitro and in vivo","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103985","article-title":"Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases","volume":"25","author":"Luo","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.118199_bib45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","article-title":"Apoptosis in cancer biology and therapy","volume":"20","author":"Moyer","year":"2025","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2025.118199_bib46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1210\/endrev\/bnab041","article-title":"Membrane-initiated estrogen, androgen, and progesterone receptor signaling in health and disease","volume":"43","author":"Mauvais-Jarvis","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2025.118199_bib47","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.jmedchem.8b01413","article-title":"Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7","volume":"62","author":"Zoppi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib48","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1021\/acs.jmedchem.0c01125","article-title":"Discovery of proteolysis-targeting chimera molecules that selectively degrade the IRAK3 pseudokinase","volume":"63","author":"Degorce","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118199_bib49","doi-asserted-by":"crossref","first-page":"11571","DOI":"10.1021\/acs.joc.8b01551","article-title":"Synthesis of selective Estrogen receptor degrader GDC-0810 via stereocontrolled assembly of a tetrasubstituted all-carbon olefin","volume":"83","author":"Savage","year":"2018","journal-title":"J. Org. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500964X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500964X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:34:36Z","timestamp":1778538876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500964X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S022352342500964X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118199","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly potent and selective degrader targeting ER\u03b1 to improve the treatment outcomes of breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118199"}}